Vascular Constructs
US-2026009164-A1 · Jan 8, 2026 · US
Use of agar-derived oligosaccharides for inhibiting growth of Staphylococcus
US11413305B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11413305-B2 |
| Application number | US-201816767928-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 20, 2018 |
| Priority date | Nov 28, 2017 |
| Publication date | Aug 16, 2022 |
| Grant date | Aug 16, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting the growth of Staphylococcus or killing the same, comprising contacting at least one type of Staphylococcus with an effective amount of one or more selected from the group consisting of an agarooligosaccharide, and agarobiose, wherein the agarooligosaccharide is a mixture of agarobiose, agarotetraose, agarohexaose, and agarooctaose, and wherein the Staphylococcus is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis , and Staphylococcus pyogenes. 2. A method for treating or alleviating a staphylococcal infectious disease in a subject, comprising administering a pharmaceutically effective amount of one or more selected from the group consisting of an agarooligosaccharide, and agarobiose to the subject in need thereof, wherein the agarooligosaccharide is a mixture of agarobiose, agarotetraose, agarohexaose, and agarooctaose, and wherein the Staphylococcus is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis , and Staphylococcus pyogenes. 3. The method of claim 2 , wherein the staphylococcal infectious disease is selected from the group consisting of an abscess, acne, dermatitis, pneumonia, endocarditis, sepsis, osteomyelitis, osteoarthritis, bacteremia, toxic shock syndrome, food poisoning, hyperthermia, edema, mastitis, and enterocolitis caused by an infection by Staphylococcus aureus, Staphylococcus epidermidis , or Staphylococcus pyogenes. 4. A method of inhibiting the growth of Staphylococcus or killing the same in an animal subject, comprising administering an effective amount of one or more selected from the group consisting of an agarooligosaccharide, and agarobiose to the animal subject in need thereof, wherein the agarooligosaccharide is a mixture of agarobiose, agarotetraose, agarohexaose, and agarooctaose, and wherein the Staphylococcus is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis , and Staphylococcus pyogenes.
Assignees
Inventors
Classifications
with singly-bound oxygen · CPC title
Preparations for care of the skin · CPC title
using additives (addition of substantially indigestible substances A23L33/21) · CPC title
Antibiotics · CPC title
containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11413305B2 cover?
- The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.
- Who is the assignee on this patent?
- Univ Korea Res & Bus Found
- What technology area does this patent fall under?
- Primary CPC classification A61K31/729. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).